Lantheus Holdings Receives FDA Complete Response Letter For LNTH-2501 Due To Manufacturing Facility Issues; No Safety Or Efficacy Concerns Identified

뉴스 본문을 불러오고 있어요.

Lantheus Holdings Receives FDA Complete Response Letter For LNTH-2501 Due To Manufacturing Facility Issues; No Safety Or Efficacy Concerns Identified | 웨이프 WAPE

Lantheus Holdings Receives FDA Complete Response Letter For LNTH-2501 Due To Manufacturing Facility Issues; No Safety Or Efficacy Concerns Identified

기사 요약

관련 종목

댓글 —